Currently out of the existing stock ratings of Daniel Brennan, 15 are a HOLD (55.56%), 9 are a BUY (33.33%), 3 are a SELL (11.11%).

Daniel Brennan

Work Performance Price Targets & Ratings Chart

Analyst Daniel Brennan, currently employed at UBS, carries an average stock price target met ratio of 66.42% that have a potential upside of 17.22% achieved within 149 days. Previously, Daniel Brennan worked at COWEN.

Daniel Brennan’s has documented 223 price targets and ratings displayed on 18 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on AVTR, Avantor at 14-Sep-2022.

Wall Street Analyst Daniel Brennan

Analyst best performing recommendations are on NVTA (INVITAE CORP).
The best stock recommendation documented was for ILMN (ILLUMINA) at 9/22/2020. The price target of $285 was fulfilled within 2 days with a profit of $16.49 (6.14%) receiving and performance score of 30.71.

Average potential price target upside

of $59.96 (17.25%) on TMO (THERMO FISHER SCIENTIFIC).
of $40.65 (14.08%) on ILMN (ILLUMINA).
of $36.33 (24.14%) on IQV (IQVIA HOLDINGS).

BRKR Bruker CRL Charles River Laboratories CTLT Catalent EXAS EXACT Sciences IQV IQVIA Holdings NEO NeoGenomics SLGC Somalogic TMO Thermo Fisher Scientific A Agilent Technologies AVTR Avantor ICLR ICON PLC ILMN Illumina MTD Mettler-Toledo International NVTA Invitae Corp TX Ternium SA ADR WAT Waters DHR Danaher NSTG NanoString Technologies

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Matthew Sykes (GOLDMAN SACHS)